The company’s stock has dropped by 15% after the Phase II trial data was announced. Image credit: Shutterstock / pathdoc Vertex Pharmaceuticals’s non-opioid-based pain therapy has shown benefit in a ...

Vertex Pharmaceuticals lost more than $15 billion in value Thursday as new data on its closely watched pain drug disappointed Wall Street. The medication is meant to be a non-addictive alternative to ...

This should hopefully be the definitive repository for Unity3d users looking to use the standard shader with meshes that have vertex colors. This shader supports everything the stock "Standard Shader" ...

Vertex Pharmaceuticals Incorporated today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan ...

Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed little difference versus a ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval molecule to a significant improvement from baseline, but placebo ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P ...

Narrow-moat Vertex released results from its phase 2 trial of suzetrigine, for the treatment of painful lumbosacral radiculopathy, and it met the primary endpoint with a statistically significant ...